The trends of the two leading weight loss drugs are diverging! Strong sales ignite Eli Lilly (LLY.US) Q2 performance exceeding expectations.

Zhitong Finance APP reported that Eli Lilly (LLY.US) announced its second-quarter performance before the market opened on Wednesday, which surpassed market expectations, mainly due to strong sales of its injectable GLP-1 medication and the newly launched oral weight-loss drug Foundayo. As of the time of publication, the company's stock was up 5%.